COPENHAGEN (Reuters) – Novo Nordisk will more than double the amount of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on Wednesday as the Danish drugmaker ramps up output of its popular therapy.
The boost in supply means some new patients can start treatment, he said.
Novo last year was unable to meet runaway demand for Wegovy, and in May began limiting the number of U.S. patients who could start treatment by reducing supply of the lowest three doses of the appetite-suppressing weekly injection.
(Reporting by Jacob Gronholt-Pedersen and Maggie Fick; writing by Josephine Mason; editing by Jason Neely)
Comments